bioAffinity Tech Stock Price, News & Analysis

bioAffinity Technologies (NASDAQ: BIAF) released a case study demonstrating the effectiveness of its CyPath® Lung diagnostic test in identifying lung cancer in a patient with ground-glass pulmonary nodules. The test successfully detected cancer in a 66-year-old former smoker who had multiple ground-glass nodules discovered during an unrelated CT scan.

The case highlights CyPath® Lung's ability to provide actionable results that can expedite treatment decisions, particularly in cases where traditional guidelines recommend 2-5 years of watchful waiting. Following the "likely malignant" test result, robotic bronchoscopy confirmed the cancer diagnosis, leading to immediate surgical treatment referral.

bioAffinity Technologies (NASDAQ:BIAF) received recognition from U.S. Medicine magazine for its CyPath® Lung diagnostic test, highlighting its potential to improve lung cancer detection in veterans while reducing VA healthcare costs. The test demonstrated 92% sensitivity, 87% specificity, and 88% accuracy in detecting nodules 20mm or smaller.

Research published in the Journal of Health Economics and Outcomes Research revealed potential savings of $895 million for private payers and $379 million for Medicare if CyPath® Lung had been integrated into the standard of care in 2022. The test has successfully detected lung cancer at Stage 1A when other diagnostic tools failed.

bioAffinity Technologies (NASDAQ: BIAF) has strengthened its Board of Directors with two strategic appointments. The company named Roberto Rios, CPA, a veteran financial executive with over 40 years of experience in biotechnology and medical devices, and Dr. John J. Oppenheimer, a distinguished clinical researcher and expert in asthma and COPD treatment.

Dr. Oppenheimer brings extensive clinical expertise with over 180 clinical studies and 260 publications, while Rios contributes significant financial leadership experience from companies including ILEX Oncology and BioMedical Enterprises. These appointments align with bioAffinity's focus on expanding CyPath® Lung sales and developing companion diagnostics for the $26 billion asthma therapeutics market. The company also announced Gary Rubin's departure from the Board for personal reasons.

bioAffinity Technologies (NASDAQ: BIAF) has completed two significant financial transactions totaling approximately $1.2 million in gross proceeds. The company closed a private placement involving 990 shares of Series B Convertible Preferred Stock and warrants to purchase about 6.7 million common stock shares.

Additionally, the company executed a warrant inducement transaction where an existing investor exercised warrants for 1.1 million shares at a reduced exercise price of $0.23 per share (down from $1.50), generating approximately $253,000 in gross proceeds. The investor received new unregistered warrants to purchase 1.4 million shares at $0.352 per share, exercisable upon stockholder approval with a five-year expiration term.

bioAffinity Technologies (NASDAQ: BIAF) reported Q2 2025 financial results, highlighting 62% year-over-year growth in CyPath® Lung test revenues for H1 2025. The company recorded total revenue of $1.3M, down from $2.4M in Q2 2024 due to discontinuation of unprofitable pathology services. Operating expenses decreased 16% to $3.8M, while net loss increased to $4.1M ($0.17 per share).

Notable achievements include a 72% increase in CyPath® Lung tests in July compared to H1 2025 monthly average, price increase to $2,900 per test, and successful completion of a $3.25M public offering. The company strengthened its position through new partnerships, patent grants in multiple countries, and the appointment of Dr. Gordon Downie as CMO.

bioAffinity Technologies (NASDAQ: BIAF), a biotechnology company focused on early-stage cancer detection, has secured approximately $1.2 million in gross proceeds through a private placement and warrant inducement transaction. The company is selling 990 shares of Series B Convertible Preferred Stock at $1,000 per share, convertible into approximately 4.3 million common shares at $0.23 per share.

The deal includes warrants to purchase about 6.7 million common shares at $0.352 per share. Additionally, an existing investor agreed to exercise warrants for 1.1 million shares at reduced prices, providing $253,000 in immediate proceeds. The transaction, managed by WallachBeth Capital, is expected to close around August 14, 2025. Proceeds will support working capital and general corporate purposes.

bioAffinity Technologies (NASDAQ: BIAF) has announced a private placement and warrant inducement transaction expected to generate approximately $1.2 million in gross proceeds. The company is selling 990 shares of Series B Convertible Preferred Stock at $1,000 per share, convertible into approximately 4.3 million common shares at $0.23 per share.

The transaction includes warrants to purchase about 6.7 million common shares at $0.352 per share. Additionally, an existing investor will exercise warrants for 1.1 million shares at reduced prices, generating $253,000 in proceeds. The closing is expected around August 14, 2025, with proceeds intended for working capital and general corporate purposes.

bioAffinity Technologies (NASDAQ: BIAF) reported significant growth in sales of its CyPath® Lung cancer diagnostic test. July test volume showed a 72% increase over the previous monthly average for H1 2025, marking consecutive record-breaking months in June and July.

The company reaffirmed its forecast of 3X year-over-year revenue growth for CyPath® Lung. The growth is attributed to increasing physician adoption and successful case studies showing the test's ability to detect Stage 1A lung cancer in cases where standard imaging and other tests indicated benign conditions.

bioAffinity is expanding beyond its successful Texas pilot program into the Mid-Atlantic region and Veterans Administration healthcare system. The company's Texas program, reaching approximately 6% of U.S. pulmonologists, has validated their marketing approach.

bioAffinity Technologies (NASDAQ: BIAF) has reported a significant case study demonstrating the effectiveness of its CyPath® Lung diagnostic test in detecting early-stage lung cancer. The test successfully identified Stage 1A pulmonary mucinous adenocarcinoma in a 62-year-old high-risk patient when other diagnostic methods showed low cancer probability.

The patient's traditional diagnostic results, including PET scan and blood-based risk test, indicated only an 11% malignancy risk. However, CyPath® Lung's test result of 0.56 classified the case as "likely malignancy," leading to successful surgical intervention through wedge resection in June 2025.

This case highlights CyPath® Lung's capability to detect rare cancer types that are often missed by standard imaging, potentially enabling life-saving early interventions.